AstraZeneca PLC (AZN) DCF Valuation

AstraZeneca PLC (AZN) DCF Valuation

GB | Healthcare | Drug Manufacturers - General | NASDAQ
AstraZeneca PLC (AZN) DCF Valuation

Fully Editable: Tailor To Your Needs In Excel Or Sheets

Professional Design: Trusted, Industry-Standard Templates

Investor-Approved Valuation Models

MAC/PC Compatible, Fully Unlocked

No Expertise Is Needed; Easy To Follow

AstraZeneca PLC (AZN) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Simplify AstraZeneca PLC (AZN) valuation with this customizable DCF Calculator! Featuring real AstraZeneca PLC (AZN) financials and adjustable forecast inputs, you can test scenarios and uncover AstraZeneca PLC (AZN) fair value in minutes.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue 26,617.0 37,417.0 44,351.0 45,811.0 54,073.0 64,946.3 78,006.0 93,691.9 112,532.0 135,160.5
Revenue Growth, % 0 40.58 18.53 3.29 18.03 20.11 20.11 20.11 20.11 20.11
EBITDA 8,084.0 5,113.0 9,085.0 13,912.0 17,121.0 16,438.1 19,743.6 23,713.8 28,482.3 34,209.6
EBITDA, % 30.37 13.66 20.48 30.37 31.66 25.31 25.31 25.31 25.31 25.31
Depreciation 2,896.0 4,102.0 5,254.0 4,934.0 6,688.0 7,381.6 8,865.9 10,648.7 12,790.0 15,361.9
Depreciation, % 10.88 10.96 11.85 10.77 12.37 11.37 11.37 11.37 11.37 11.37
EBIT 5,188.0 1,011.0 3,831.0 8,978.0 10,433.0 9,056.6 10,877.7 13,065.0 15,692.2 18,847.7
EBIT, % 19.49 2.7 8.64 19.6 19.29 13.94 13.94 13.94 13.94 13.94
Total Cash 7,992.0 6,398.0 6,405.0 5,860.0 5,654.0 11,016.8 13,232.1 15,892.9 19,088.7 22,927.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 3,806.0 6,031.0 7,212.0 8,407.0 .0
Account Receivables, % 14.3 16.12 16.26 18.35 0
Inventories 4,024.0 8,983.0 4,699.0 5,424.0 5,288.0 9,266.6 11,129.9 13,368.0 16,056.1 19,284.8
Inventories, % 15.12 24.01 10.6 11.84 9.78 14.27 14.27 14.27 14.27 14.27
Accounts Payable 2,350.0 2,824.0 2,550.0 3,267.0 22,465.0 9,196.8 11,046.1 13,267.3 15,935.2 19,139.6
Accounts Payable, % 8.83 7.55 5.75 7.13 41.55 14.16 14.16 14.16 14.16 14.16
Capital Expenditure -2,606.0 -2,200.0 -2,571.0 -3,778.0 -4,586.0 -4,961.3 -5,958.9 -7,157.2 -8,596.4 -10,325.0
Capital Expenditure, % -9.79 -5.88 -5.8 -8.25 -8.48 -7.64 -7.64 -7.64 -7.64 -7.64
Tax Rate, % 19.05 19.05 19.05 19.05 19.05 19.05 19.05 19.05 19.05 19.05
EBITAT 4,234.1 -427.3 5,036.5 7,749.5 8,445.1 6,319.2 7,589.9 9,116.2 10,949.3 13,151.0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -955.9 -5,235.3 10,548.5 7,702.5 38,288.1 -16,954.2 8,784.3 10,550.7 12,672.3 15,220.5
WACC, % 5.19 4.12 5.43 5.25 5.18 5.03 5.03 5.03 5.03 5.03
PV UFCF
SUM PV UFCF 23,243.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 15,525
Terminal Value 511,602
Present Terminal Value 400,195
Enterprise Value 423,438
Net Debt 24,626
Equity Value 398,812
Diluted Shares Outstanding, MM 1,560
Equity Value Per Share 255.65

What You Will Get

  • Comprehensive AZN Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust parameters such as WACC, tax rates, revenue growth, and capital expenditures.
  • Dynamic Calculations: Intrinsic value and NPV are calculated in real-time.
  • Scenario Analysis: Evaluate various scenarios to assess AstraZeneca’s future performance.
  • User-Friendly Design: Tailored for professionals while remaining approachable for newcomers.

Key Features

  • Customizable Forecast Inputs: Adjust essential metrics such as revenue growth, EBITDA %, and capital investments.
  • Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other financial metrics.
  • High-Precision Accuracy: Incorporates AstraZeneca’s actual financial data for credible valuation results.
  • Effortless Scenario Analysis: Evaluate various assumptions and analyze outcomes with ease.
  • Efficiency Booster: Avoid the hassle of creating intricate valuation models from the ground up.

How It Works

  • Download: Obtain the pre-built Excel file containing AstraZeneca PLC's (AZN) financial data.
  • Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Develop various forecasts and compare results instantly.
  • Make Decisions: Leverage the valuation insights to inform your investment approach.

Why Choose AstraZeneca PLC (AZN) Calculator?

  • Save Time: Instantly access a pre-built DCF model without the hassle of starting from scratch.
  • Enhance Accuracy: Utilize dependable financial data and formulas to minimize valuation errors.
  • Completely Customizable: Adjust the model to align with your specific assumptions and forecasts.
  • User-Friendly: Intuitive charts and outputs simplify the analysis of results.
  • Preferred by Professionals: Crafted for experts who prioritize precision and ease of use.

Who Should Use This Product?

  • Investors: Evaluate AstraZeneca’s valuation prior to making stock transactions.
  • CFOs and Financial Analysts: Enhance valuation workflows and assess financial forecasts.
  • Startup Founders: Understand the valuation methods applied to leading public companies like AstraZeneca.
  • Consultants: Provide detailed valuation reports for your clients.
  • Students and Educators: Utilize real-world examples to practice and teach valuation methodologies.

What the Template Contains

  • Comprehensive DCF Model: Editable template with detailed valuation calculations for AstraZeneca PLC (AZN).
  • Real-World Data: AstraZeneca's historical and projected financials preloaded for analysis.
  • Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to test various scenarios.
  • Financial Statements: Full annual and quarterly breakdowns for deeper insights into AstraZeneca's performance.
  • Key Ratios: Built-in analysis for profitability, efficiency, and leverage specific to AstraZeneca PLC (AZN).
  • Dashboard with Visual Outputs: Charts and tables for clear, actionable results tailored to AstraZeneca PLC (AZN).


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.

No products were found matching.